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Strengths and limitations of this study
 ► This is a prospectively conducted multicentre na-
tional study in which patient data will be captured in 
a pragmatic clinical setting.
 ► Patients will be recruited for clinically indicated
genomic testing for suspected genetic kidney dis-
orders, which may allow better generalisability of
results.
 ► Genomic testing is clinically indicated and per-
formed routinely in some participating states/cen-
tres in Australia, and therefore it would be unethical
to have a control arm for comparison as this would
deny some patients of testing.
 ► This study will contribute to the future research and
clinical service redesign by establishing the utility
of genomic testing in a kidney disease cohort from
patient, clinician and health resource perspectives.
ABSTRACT
Introduction Recent advances in genomic technology 
have allowed better delineation of renal conditions, the 
identification of new kidney disease genes and subsequent 
targets for therapy. To date, however, the utility of genomic 
testing in a clinically ascertained, prospectively recruited 
kidney disease cohort remains unknown. The aim of this 
study is to explore the clinical utility and cost-effectiveness 
of genomic testing within a national cohort of patients 
with suspected genetic kidney disease who attend 
multidisciplinary renal genetics clinics.
Methods and analysis This is a prospective observational 
cohort study performed at 16 centres throughout Australia. 
Patients will be included if they are referred to one of the 
multidisciplinary renal genetics clinics and are deemed 
likely to have a genetic basis to their kidney disease by the 
multidisciplinary renal genetics team. The expected cohort 
consists of 360 adult and paediatric patients recruited by 
December 2018 with ongoing validation cohort of 140 
patients who will be recruited until June 2020. The primary 
outcome will be the proportion of patients who receive a 
molecular diagnosis via genomic testing (diagnostic rate) 
compared with usual care. Secondary outcomes will include 
change in clinical diagnosis following genomic testing, 
change in clinical management following genomic testing 
and the cost-effectiveness of genomic testing compared with 
usual care.
Ethics and dissemination The project has received 
ethics approval from the Melbourne Health Human 
Research Ethics Committee as part of the Australian 
Genomics Health Alliance protocol: HREC/16/MH/251. 
All participants will provide written informed consent for 
data collection and to undergo clinically relevant genetic/
genomic testing. The results of this study will be published 
in peer-reviewed journals and will also be presented at 
national and international conferences.
InTRoduCTIon
Genetic kidney disease (GKD) accounts for 
10% of adults with chronic kidney disease 
(CKD),1 with a monogenic cause being iden-
tified in around 20% of those with early-
onset CKD.2 Recent advances in genomic 
sequencing have enabled rapid and cost-ef-
fective sequencing of large amounts of DNA3 
via massively parallel sequencing, otherwise 
known as next generation sequencing (NGS). 
This, in turn, has led to better delineation of 
GKD, the identification of new renal disease 
genes and subsequent targets for therapy.4 
Moreover, the clinical implementation of 
genomic testing has increased the number 
of patients receiving a timely and accurate 
genetic diagnosis.5 NGS-based genetic testing 
has demonstrated a monogenic cause in 20% 
of patients with early-onset CKD, and almost 
10% in an unselected cohort of 3000 adults 
with CKD.2 6 A genomic diagnosis has many 
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Figure 1 Participating renal genetics clinics.
potential benefits including enabling targeted thera-
pies,7–9 preventing the use of inappropriate treatments10 
and reducing the use of invasive diagnostic investigations 
such as renal biopsy. In addition to concluding a some-
times protracted diagnostic odyssey, a genomic diagnosis 
may also provide prognostic information, inform targeted 
surveillance for extrarenal complications and facilitate 
transplantation and reproductive planning. Despite these 
potential benefits, there is a paucity of comprehensive 
evaluations of clinical utility and health economic impact 
of genomic testing in kidney disease cohorts.
Multifaceted novel approaches are required to address 
the complexities of successfully implementing genomic 
technologies into clinical care. Diagnostic renal genetics 
clinics (RGC) apply a multidisciplinary team approach 
through collaboration between adult and paediatric 
nephrologists, clinical geneticists, genetic counsellors 
and diagnostic laboratory scientists. While RGCs are oper-
ational in several countries, there is a lack of reported 
outcomes of this clinical model of care.5 11
The purpose of this study is to comprehensively deter-
mine the clinical utility and cost-effectiveness of genomic 
testing in patients with suspected GKD seen in a multidis-
ciplinary RGC, and to compare this with their care and 
clinical diagnosis prior to referral. In addition, we aim to 
evaluate the value of a multidisciplinary RGC model from 
a patient perspective.
STudy AIMS
1. To determine the proportion of patients with suspect-
ed GKD who obtain a positive diagnosis following
genomic testing compared with their clinical diagnosis 
prior to testing.
2. To determine the clinical impact of genomic testing
after 3 months’ follow-up in a cohort of patients with
suspected GKD and identify subgroups of patients who
are more likely to have a clinical impact following ge-
nomic testing.
3. To determine whether genomic testing in a cohort of
patients with suspected GKD is cost-effective compared
with usual care, and to identify whether genomic test-
ing is cost-effective for specific subgroups.
4. To provide access to further research genomics partic-
ipation for patients with suspected GKD who remain
undiagnosed following clinical genomic testing.
5. To determine patient preferences regarding a service
delivery model for a dedicated renal genetics service.
6. To determine the value of genomic testing in those
with suspected GKD from a patient perspective.
METhodS And AnAlySIS
Study design
This prospective observational study will be undertaken 
at multiple Australian sites that provide multidisciplinary 
renal genetics services. There are 16 participating sites 
throughout Australia (figure 1). Patients who are referred 
by their treating physician to these multidisciplinary 
RGCs will be recruited over 4 years (figure 2). Patients 
may be referred for testing for a variety of reasons. These 
include confirmation of a suspected diagnosis, exclusion 
of differential diagnoses, clarification of mode of inheri-
tance and for obtaining the diagnosis where one is previ-
ously unknown. For this reason, it was not possible to 
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Figure 2 Patient flow within a KidGen Renal Genetics Clinic. MDT, multidisciplinary team.
include a control arm, as this would prevent some patients 
from undergoing their usual clinical care. In order to 
enable determination of comparative clinical utility, 
planned diagnostic investigations will be nominated by 
the recruiting clinicians. In addition, data regarding any 
changes in management will be collected from the refer-
ring nephrologist at 3 months following the return of 
genomic testing results.
Recruitment of a baseline cohort of 360 participants 
occurred between 2017 and 2018 (figure 3) and a further 
mutually exclusive replication cohort will be recruited 
between 2019 and 2020. The replication cohort will have 
the same data collected but will also include patients with 
a prior genomic diagnosis. These patients will not partic-
ipate in evaluation surveys (described below) but will be 
evaluated against all other outcome measures in order to 
further identify patient, disease and subcohort clinical 
outcomes enabled by larger scale and longer time span 
observation. The cohort of patients is anticipated to be 
ethnically diverse with a broad spectrum of renal pheno-
types, clinical diagnoses and severity of kidney disease. 
Patients seen in a multidisciplinary RGC as part of stan-
dard clinical care will be invited to participate in the study 
if there is consensus of opinion by the clinic team that 
their kidney disease is likely genetic in origin. Patients 
without a clear clinical indication for prospective clinical 
genomic testing will be excluded in the baseline cohort, 
including an existing molecularly confirmed genetic diag-
nosis and those with heterogeneous or complex diseases 
with a low or unlikely monogenic diagnosis rate by 
current genomic sequencing (such as isolated congenital 
abnormalities of the kidney and urinary tract).12 Patients 
who undergo only Sanger sequencing are excluded from 
the study as this would not represent a genomic approach 
to clinical investigation and may instead represent clar-
ification or segregation of an already identified familial 
variant. Patients who attend an RGC but do not undergo 
genetic testing through the clinic are also excluded from 
the study. This includes patients who decline clinically 
indicated testing. Written informed consent, both for 
clinical genomic testing and participation in the research 
study, will be obtained by the nominated clinical geneti-
cist, nephrologist or genetic counsellor at each site.
Participant identifiers
All participants will be assigned a unique identifier for 
the purposes of this study at recruitment. Study data 
will be collected and managed using REDCap13 elec-
tronic data capture tools hosted at Murdoch Children’s 
Research Institute. Access to patient identifying details is 
restricted to clinicians providing care and to those who 
need contact details for evaluation purposes.
Measures
Once consented to the study, baseline demographic 
information, clinical information and detailed pheno-
typic information will be recorded by clinicians in 
REDCap. Demographic data including age, gender, 
ethnicity and English language status will be captured for 
all recruited patients. Further demographic information 
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Figure 3 Recruitment workflow within the KidGen Renal Genetics Clinic network. CKD, chronic kidney disease; REDCap, 
Research Electronic Data Capture; RGC, renal genetics clinics.
will be captured in patient surveys. Clinical data include 
suspected clinical diagnosis, comorbidities and types of 
specialists previously seen. A detailed family history and 
pedigree will be collected to identify the number of 
probands and at-risk relatives presenting for assessment. 
Comprehensive phenotypic information will also be 
collected including the presence of extrarenal features, 
renal impairment, urea and creatinine level, CKD stage, 
presence and details of hypertension, haematuria, 
proteinuria and biochemical/haematological abnormal-
ities, results of imaging including ultrasound, CT and 
MRI, and results of renal biopsy if already performed. 
Data will also be collected regarding type of genomic test, 
outcomes of test and time taken to achieve diagnosis. 
Clinical diagnosis will be recorded as listed in the referral 
of each patient to the RGC, at the time of triaging for the 
RGC, prior to genomic testing and at the time of return 
of genomic testing results. This will enable comparison 
across multiple time points potentially leading up to a 
molecular genetic diagnosis.
Patient and public involvement
The project was reviewed, edited and revised after in-depth 
engagement with the Australian Genomic Health Alliance 
Consumer and Community Advisory group. Previous 
informal engagement with relevant representative local 
Australian kidney health patient organisations, including 
Polycystic Kidney Disease Australia and Kidney Health 
Australia, also occurred. Results from this study will be 
published and be accessible to all patients on request.
Evaluation surveys
Evaluation surveys will be distributed to be completed 
either online or on paper. Adult and proxy versions are 
available (parent for child). Participants are asked to 
complete the first survey at 2–3 weeks after attending the 
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Table 1 Summary of survey measures
Measure Description S1 S2
Demographics Age, gender, marital status, education, income, number of dependents in household, 
postcode, private health insurance status.
X
Patient-reported outcome 
measures
CHU9D and PedsQL family impact for paediatric surveys
OR
SF-12 for adult surveys
X X
Experience of the 
multidisciplinary clinic
Three study-specific questions exploring advantages and disadvantages of 
multidisciplinary renal genetics clinics.
X X
Genetic counselling 24-item scale measuring outcomes of genetic counselling GCOS-24 . X X
Family planning Four study-specific questions addressing plans for another child, estimated 
recurrence of the kidney condition, concern about recurrence, interest in 
reproductive technologies (parent surveys only).
X
Understanding In survey 1, eight study-specific questions address participant understanding 
of: types of potential results (four questions), potential familial implications (one 
question), ways in which the data can be used (two questions) and number of genes 
examined (one question).
In survey 2, two study-specific questions used to measure recall and understanding 
of result.
X X
Willingness to pay (value) Study-specific questions included to establish a quantitative reference for the value 
placed on testing.
X X
Information provision Study-specific questions to assess participant perception about the way in which 
information (3 items—S1) and results (3 items—S2) were provided.
X X
Hopes/expectation Eight study-specific questions exploring participants’ reasons for agreeing to the 
test, rated on a 5-point scale as extremely unimportant to extremely important.
X
Likelihood One study-specific question to determine participant’s perception of the likelihood 
testing will find the cause of the condition.
X
Decision regret 5-item scale measuring distress or remorse after a (healthcare) decision (ref
O’Connor).18
X
Value of the test Eleven study-specific questions exploring the value to participants of having had the 
test rated on a 4-point scale as not valuable to extremely valuable or not applicable.
X
Impact of the test Two study-specific questions asking about the impact of the test on family planning. X
CHU9D, Child Health Utility 9D instrument; GCOS-24, Genetic Counselling Outcome Scale; PedsQL, Pediatric Quality of Life Inventory; SF-
12, 12-Item Short Form Health Survey.
RGC at which they are offered and consent to testing, and 
the second following their receipt of genomic test results. 
The surveys were developed based on existing surveys in 
use in the Melbourne Genomics Health Alliance.
The first survey (table 1) captures additional demo-
graphic information and also includes questions about 
the experience of the consent process and views on the 
benefits of the multidisciplinary RGC. The Genetic Coun-
selling Outcomes Survey14 is included in surveys 1 and 2 
to evaluate genetic counselling outcomes of the multidis-
ciplinary clinic. Knowledge questions and a question on 
the likelihood of the test finding the cause of the kidney 
disease are included in survey 1 to gauge understanding. 
The first survey includes closed and open questions 
exploring hopes and expectations for testing. Willing-
ness-to-pay questions designed specifically for this study 
are included in both surveys to gauge value. Validated 
multiattribute quality of life instruments (12-Item Short 
Form Health Survey (SF-12) for adults and parents,15 
Child Health Utility 9D instrument for children16) are 
included in surveys 1 and 2 to assess health-related quality 
of life. The Pediatric Quality of Life Inventory17 family 
impact module is included in surveys 1 and 2 for parents 
to assess family impact. Both surveys include questions on 
family planning.
In addition to the measures described above, the 
second survey includes study-specific questions assessing 
understanding of the genomic results, the impact this will 
have on the patient and their family and perceived value 
of genomic testing. The Decision Regret Scale18 is also 
included in survey 2.
Sequencing
Genomic sequencing will be undertaken and reported 
in clinically accredited laboratories. It is envisaged that 
these are likely to include but not be limited to the 
National Association of Testing Authorities accredited 
diagnostic laboratories at Children’s Hospital at West-
mead, Victorian Clinical Genetics Service, Genome.
One, SA Pathology and PathWest. The specific clinical 
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test requested for each participant will be selected by 
the treating clinician/s at the attending RGC according 
to clinical indication. The spectrum of genomic testing 
that will be employed is anticipated to include targeted 
exome, whole exome and whole genome sequencing, 
including the application of virtual gene panels based on 
patient phenotype. When additional copy number varia-
tion assessment and/or variant confirmation is indicated, 
then multiplex ligation-dependent probe application, 
chromosomal microarray or Sanger sequencing may be 
undertaken in addition to genomic sequencing. The cost 
per test is expected to be $A1200–$A2400 depending 
on the specific test and diagnostic provider, with indi-
vidual test costs to be ascertained directly. Further, each 
participant will have genomic sequencing performed 
once unless technical or sequence quality issues require 
resequencing to enable clinical reporting. Based on 
clinical indication, further analysis of disease or pheno-
type-specific virtual gene panels may occur, with any such 
sequence reanalysis being recorded.
All participants will provide written clinical consent 
for genomic testing and analysis will be restricted to the 
assessment of genes related to the condition of interest. 
In this instance, analysis will be limited to a predefined 
gene list of 360 genes related to nephropathy.19 Secondary 
findings unrelated to the presenting condition will not be 
reported in this study. Written informed consent for partic-
ipation in the research study will be attained separately, 
which includes options to consent to accessing the Medi-
care Benefits Schedule (MBS) and Pharmaceutical Bene-
fits Scheme (PBS), hospital and emergency data sets and 
data sharing in addition to study evaluation data collec-
tion. The MBS and PBS are listings of all medical services 
and medicines subsidised by the Australian government, 
respectively. In addition, an optional written consent will 
be obtained in order to share data and samples for use in 
ethically approved research outside of the study.
health economic evaluation
An economic evaluation will be conducted to assess the 
incremental cost-effectiveness of NGS compared with 
usual care in patients with suspected kidney disease. A 
microsimulation model of disease progression will be 
developed to estimate the lifetime costs and outcomes 
associated with usual care and NGS. The analysis will be 
conducted from an Australian healthcare system perspec-
tive in line with recommended practices,20–22 and based 
on the outcomes of cost per additional diagnosis, cost per 
quality-adjusted life year and net monetary benefit.
Hospital patient-level resource use and cost data will be 
acquired for each study participant to cost the diagnostic 
and short-term medical management in the NGS arm. 
The additional per-patient diagnostic investigations that 
could potentially be incurred in the usual care pathway 
will be identified based on a review of national and inter-
national guidelines on the diagnosis of suspected kidney 
disease and clinical expertise from each of the 16 partic-
ipating centres across Australia. The Australia and New 
Zealand Dialysis and Transplant Registry will be used 
to undertake a survival analysis of patients with CKD. 
Parametric and non-parametric methods will be used 
to estimate transition probabilities for key endpoints, 
including: all-cause mortality, initiation of dialysis and 
transplantation. This will allow for the development of 
evidence-based transition probabilities while controlling 
for patient-specific factors such as age, gender, treatment 
pathways and disease status. Unit costs associated with 
these endpoints and related treatments will be drawn 
from established national sources.23–25 A microsimulation 
will be used to capture the costs and benefits associated 
with earlier renal replacement therapy and delayed dial-
ysis from the introduction of NGS. To accurately model 
the implications, registry-derived transition probabilities 
will be adjusted, on the basis of published evidence,26 to 
reflect the impact of new treatment pathways following 
NGS.
For the cost-utility analysis, participants’ responses to 
the SF-12 measure will initially be used to generate util-
ities at baseline prior to NGS and following the return 
of NGS findings. A review of the literature will be under-
taken to complement these estimates with evidence from 
secondary sources, such as utilities for CKD27 and renal 
transplantation.28 The cost-benefit analysis will rely on 
a contingent valuation exercise that was undertaken to 
understand the personal value of NGS to the families. 
Deterministic and probabilistic sensitivity analyses will 
be undertaken to explore the robustness of the findings 
to plausible variations in key assumptions around costs, 
outcomes and transition probabilities, and to consider 
the broader issue of generalisability of the study’s results. 
Cost-effectiveness acceptability curves will be generated 
to reflect decision uncertainty.
Study outcomes
The primary outcome will be the proportion of patients 
who receive a molecular diagnosis via genomic testing 
(diagnostic rate). Secondary outcomes will be change 
in clinical diagnosis following genomic testing, change 
in clinical management following genomic testing and 
cost-effectiveness of genomic testing compared with 
non-genomic diagnostic investigations. Survey outcomes 
will include the proportion of patients who preferred 
to be seen by the multidisciplinary team compared with 
those who preferred to be seen in individual clinics. In 
addition, the Genetic Counselling Outcome Scale will 
be compared before and after testing and between those 
with a positive/negative genomic testing result.
data analysis
Results on diagnostic utility and clinical implications 
will be expressed as frequencies and percentages for 
categorical variables and be compared using the χ2 test. 
Continuous non-normally distributed variables will be 
expressed as median (IQR) and compared using the 
Mann-Whitney test. Normally distributed continuous vari-
ables will be expressed as mean±SD and compared using 
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the Student’s t-test. Multivariable logistic regression will 
be performed to determine which variables may predict a 
positive genomic diagnosis, such as age of onset of CKD, 
aetiology of CKD, family history or presence of haema-
turia/proteinuria/cysts. This will help develop profes-
sional guidelines regarding genomic testing in suspected 
GKD. In addition, the diagnostic rates between different 
genomic testing modalities will also be compared. The 
target sample size is 500 patients across both baseline and 
replication cohorts.
dISCuSSIon
In this protocol, we describe the rationale and methods 
for a prospective observational study of a national cohort 
of patients with suspected genetic renal disease that are 
referred to multidisciplinary RGCs throughout Australia. 
The strengths of this study are the multicentre design, 
prospective data collection and a real-world clinical 
setting. The absence of a control arm is a limitation of this 
study, however it was not feasible to randomise patients in 
this study for two reasons. First, genomic testing is clini-
cally indicated and performed routinely in most partici-
pating states/centres, and it would therefore be unethical 
to deny genomic testing to some patients where it is clin-
ically indicated and current standard of care. Second, 
feedback from patient representatives, the community 
and genetic counsellors highlighted that it was unaccept-
able to deny testing to some patients for the purpose of 
a control arm. Further, those patients not receiving a 
genomic test after clinical assessment are likely to do so 
in a non-random fashion thus precluding their analysis as 
a true control group.
Genomic technologies have transformed the concept 
of precision medicine in many specialties, however the 
potential benefits in kidney medicine are yet to be demon-
strated. Until now, the diagnostic utility of genomic 
testing has been assessed in a small number of patients or 
in a research context.29 30 In addition, while studies which 
perform genomic sequencing in larger cohorts6 31 are 
emerging, detailed phenotypic information is not being 
collected and there remains a paucity of data on clinical 
outcomes. Importantly, these large-scale studies include 
patients with all types of CKD and are thus powered to 
understand prevalence of GKD rather than to deter-
mine utility and yield in a cohort in which the clinician 
suspects genetic disease.6 Data on genomic sequencing 
in a real-world clinical environment at a national scale 
for a targeted population of patients with suspected GKD 
are lacking and the health economic impacts of genomic 
testing are not well understood or established.32 We believe 
that collecting such detailed information from a prospec-
tively ascertained cohort will enable us to determine the 
diagnostic yield and comprehensive clinical implications, 
to inform future practice recommendations.
To our knowledge, this is the first time that a structured, 
objective and minimally bias approach is undertaken 
to measure the outcomes of genomic testing in kidney 
disease. Results from this study will provide the oppor-
tunity to determine the clinical implications of genomic 
testing in a large cohort of patients, and further enable 
analysis of which subgroups of patients may benefit most. 
Furthermore, due to the pragmatic nature of this study, 
these results more likely to be replicated in a clinical envi-
ronment. By assessing the utility, cost-effectiveness and 
implementation aspects of genomic testing in patients 
with kidney disease, the results of this study will inform 
patients, treating physicians and health services and 
define priorities for future trials. Collectively, this is antic-
ipated to have significant impacts on clinical practice and 
health service redesign.
Ethics and dissemination
Ethics
Ethics approval for this project has been obtained by 
Australian Genomics Health Alliance as part of the 
research study, Australian Genomics Health Alliance: 
Preparing Australia for Genomic Medicine, and issued 
by Melbourne Health HREC/16/MH/251. Governance 
site-specific approval for the project has been obtained 
for each of the participating clinic sites. All participants 
will provide written informed consent for data collec-
tion and to undergo clinically relevant genetic/genomic 
testing.
Dissemination plan
The main findings of this study will be published in 
peer-reviewed journals and will also be presented at 
national and international conferences. We will also issue 
reports of results of the study to the Australian Govern-
ment, State/Territory Governments and health organi-
sations in order to inform future policy and guidelines. 
This study will also contribute to the training and devel-
opment of postdoctoral students.
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